CAR T-cell therapy: how can we improve toxicity management

During the 3rd Annual Meeting of the International Academy for Clinical Hematology (IACH), the ALL Hub was pleased to speak to Jordan Gauthier, Fred Hutchinson Cancer Research Center, Seattle, US. We asked: How can we improve toxicity management in patients receiving CAR T-cell therapy for acute lymphoblastic leukemia (ALL)?

Jordan Gauthier gives a detailed discussion on the current and investigational approaches for the prevention and management of main toxicities related to CAR T-cell therapy, cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS).